CN Patent

CN103502245A — (2s，3r，4r，5s，6r)-2-(3-((5-(4-氟苯基)噻吩-2-基)甲基)-4-甲基苯基)-6-(羟甲基)四氢-2h-吡喃-3，4，5-三醇的l-脯氨酸和柠檬酸共晶体

Assigned to Janssen Pharmaceutica NV · Expires 2014-01-08 · 12y expired

What this patent protects

本发明涉及(2S，3R，4R，5S，6R)-2-(3-((5-(4-氟苯基)噻吩-2-基)甲基)-4-甲基苯基)-6-(羟甲基)四氢-2H-吡喃-3，4，5-三醇的L-脯氨酸和柠檬酸共晶体、包含所述共晶体的药物组合物、以及它们在治疗葡萄糖相关失调诸如2型糖尿病和X综合征中的用途。

USPTO Abstract

本发明涉及(2S，3R，4R，5S，6R)-2-(3-((5-(4-氟苯基)噻吩-2-基)甲基)-4-甲基苯基)-6-(羟甲基)四氢-2H-吡喃-3，4，5-三醇的L-脯氨酸和柠檬酸共晶体、包含所述共晶体的药物组合物、以及它们在治疗葡萄糖相关失调诸如2型糖尿病和X综合征中的用途。

Drugs covered by this patent

fenfluramine-hydrochloride (FENFLURAMINE HYDROCHLORIDE)

Patent Metadata

Patent number: CN103502245A
Jurisdiction: CN
Classification: —
Expires: 2014-01-08
Drug substance claim: No
Drug product claim: No
Assignee: Janssen Pharmaceutica NV
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.